Ignite Creation Date:
2024-05-06 @ 2:37 AM
Last Modification Date:
2024-10-26 @ 11:20 AM
Study NCT ID:
NCT02081066
Status:
COMPLETED
Last Update Posted:
2021-08-26
First Post:
2014-02-10
Brief Title:
Identification of CETP as a Marker of Atherosclerosis
Sponsor:
Institut National de la Santé Et de la Recherche Médicale France
Organization:
Institut National de la Santé Et de la Recherche Médicale France
Study Overview
Official Title:
Relationship Between Endogenous CETP Activity and Atherosclerosis Distribution in Patients With High Cardiovascular Risk
Status:
COMPLETED
Status Verified Date:
2021-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CETP-ATHERO
Brief Summary:
The reverse cholesterol transport RCT pathway which involves the centripetal movement of free cholesterol from peripheral tissues including the vessel wall to the liver represent the primary mechanism by which HDL protects against atherosclerosis and by which it may induce plaque regression Recent data reveal that the capacity of HDL to efflux cholesterol from macrophages a metric of HDL function reflecting the initial step of the RCT is clinically relevant displaying a strong inverse association with both carotid intima-media thickness and the severity of angiographic CAD such observations were independent of HDL-C levels
In human the Cholesteryl Ester Transfer Protein CETP represents a key protein of the RCT pathway and mediates redistribution of neutral lipids between lipoproteins has been identified as a potential therapeutic target against atherosclerosis It is known that CETP activity correlates with HDL-C levels and represents a key modulator of the ability of whole plasma to mediate free cholesterol efflux from human macrophages
Recent studies showed that 23 of endogenous plasma CETP activity variability is explained by plasma LDL-C 120 HDL-C 64 and TG 44 whereas sex and BMI accounted together for only 07 of its variability Scoring patients for cardiovascular risk on the basis of their plasma lipid levels TC TG LDL-C and HDL-C revealed that patients with high cardiovascular risk score 3 displayed a mean endogenous plasma CETP activity above 34 Therefore plasma CETP activity represents a potent indicator of cardiovascular risk in patients with metabolic disorders since it integrates major independent risk factors
The objective of this study is to decipher the relationship between CETP HDL efflux capacity and the development of atherosclerosis in humans in order to identify CETP as a potent biomarker of atherosclerosis distribution
In human the Cholesteryl Ester Transfer Protein CETP represents a key protein of the RCT pathway and mediates redistribution of neutral lipids between lipoproteins has been identified as a potential therapeutic target against atherosclerosis It is known that CETP activity correlates with HDL-C levels and represents a key modulator of the ability of whole plasma to mediate free cholesterol efflux from human macrophages
Recent studies showed that 23 of endogenous plasma CETP activity variability is explained by plasma LDL-C 120 HDL-C 64 and TG 44 whereas sex and BMI accounted together for only 07 of its variability Scoring patients for cardiovascular risk on the basis of their plasma lipid levels TC TG LDL-C and HDL-C revealed that patients with high cardiovascular risk score 3 displayed a mean endogenous plasma CETP activity above 34 Therefore plasma CETP activity represents a potent indicator of cardiovascular risk in patients with metabolic disorders since it integrates major independent risk factors
The objective of this study is to decipher the relationship between CETP HDL efflux capacity and the development of atherosclerosis in humans in order to identify CETP as a potent biomarker of atherosclerosis distribution
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2013-A00798-37 | REGISTRY | IDRCB | None |